BRIEF-Elevance Health Q3 Adjusted EPS USD 6.99 Vs. IBES Estimate USD 4.68
Reuters2026/10/21 10:01Oct 21 (Reuters) - Elevance Health Q3 operating revenue USD 50,400 million.
- Q3 EPS USD 6.27
- Q3 benefit expense ratio 90.6%
- outlook FY EPS USD 22
- outlook FY adjusted EPS USD 29 vs. IBES estimate USD 27.2
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.
Crypto prices
More
